$0.17
-0.01 (-6.15%)
Open$0.20
Previous Close$0.18
Day High$0.20
Day Low$0.16
52W High$3.87
52W Low$0.14
Volume—
Avg Volume18.70M
Market Cap82.13M
P/E Ratio—
EPS$-0.78
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+16,215.5% upside
Current
$0.17
$0.17
Target
$27.41
$27.41
$18.46
$27.41 avg
$44.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 107.59M | 95.94M | 101.30M |
| Net Income | -378,166,225 | 13.15M | 13.02M |
| Profit Margin | -351.5% | 13.7% | 12.9% |
| EBITDA | -378,927,123 | 20.01M | 19.52M |
| Free Cash Flow | — | 11.25M | 11.45M |
| Rev Growth | — | +8.6% | -0.1% |
| Debt/Equity | 6.70 | 1.02 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |